Compared with placebo, mavorixafor reduced annualized infection rate, but not infection severity or warts, and is now FDA-approved for WHIM syndrome.18 Compared with G-CSF, plerixafor was not superior for infection severity; partial and sometimes complete wart regression occurred only on plerixafor.17 Plerixafor (combined with G-CSF) was FDA-approved in 2009 for hematopoietic stem cell (HSC) mobilization. Here, CSF3 is linked to infection.